Tag Archives: VBLT

Chardan Capital Sticks to Their Hold Rating for Vascular Biogenics (VBLT)

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Hold rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.21. Livshits observed: “We understand the colon

H.C. Wainwright Reiterates a Buy Rating on Vascular Biogenics (VBLT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3. The company’s shares closed yesterday at $1.21. According to TipRanks.com, Ramakanth has currently no stars on

H.C. Wainwright Thinks Vascular Biogenics’ Stock is Going to Recover

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3. The company’s shares closed yesterday at $1.16, close to its 52-week low of $0.60. Ramakanth observed:

Vascular Biogenics (VBLT) Gets a Hold Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3. The company’s shares opened today at $1.10, equals to its 52-week low of $1.10. Amusa commented:

H.C. Wainwright Keeps a Buy Rating on Vascular Biogenics (VBLT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3. The company’s shares opened today at $1.10, equals to its 52-week low of $1.10. Ramakanth observed:

Vascular Biogenics (VBLT) Gets a Hold Rating from H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Vascular Biogenics (NASDAQ: VBLT) today and set a price target of $3. The company’s shares closed on Friday at $1.65, close to its 52-week low of $1.58. According to TipRanks.com,